BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 15828547)

  • 21. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
    Ingle JN
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1031s-1036s. PubMed ID: 16467121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
    Prescrire Int; 2005 Jun; 14(77):108-10. PubMed ID: 15984106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Panasci LC
    J Clin Oncol; 2001 May; 19(9):2578; author reply 2580-2. PubMed ID: 11331341
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL;
    J Clin Oncol; 2007 May; 25(15):2006-11. PubMed ID: 17452676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of the BIG results: the Breast International Group 1-98 trial analyses.
    Doughty JC
    Breast; 2008 Jan; 17 Suppl 1():S9-S14. PubMed ID: 18279765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anastrozole (Arimidex) vs. tamoxifen for treatment of early breast cancer.
    Med Lett Drugs Ther; 2003 Mar; 45(1152):22-3. PubMed ID: 12637893
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Letrozole: advancing hormone therapy in breast cancer.
    Lee RJ; Armstrong AC; Wardley AM
    Womens Health (Lond); 2012 Nov; 8(6):611-8. PubMed ID: 23181527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New developments in the treatment of postmenopausal breast cancer.
    Howell A
    Trends Endocrinol Metab; 2005 Nov; 16(9):420-8. PubMed ID: 16213745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New treatment option for postmenopausal women with early breast cancer.
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):617. PubMed ID: 12503198
    [No Abstract]   [Full Text] [Related]  

  • 32. Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
    Okunade G; Green AR; Ying M; Agrawal A; Paish EC; Aleskandrany M; Winterbottom L; Hassell K; Morgan DA; Ellis IO; Cheung KL
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):76-82. PubMed ID: 19515574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
    Bruntsch U
    MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
    El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
    Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
    Duffy SR; Taylor L
    Am J Obstet Gynecol; 2004 Dec; 191(6):1921-7. PubMed ID: 15592273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toremifene and letrozole for advanced breast cancer.
    Med Lett Drugs Ther; 1998 Apr; 40(1024):43-5. PubMed ID: 9580744
    [No Abstract]   [Full Text] [Related]  

  • 37. Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.
    Altundag K; Altundag O
    J Clin Oncol; 2003 Dec; 21(24):4656; author reply 4657. PubMed ID: 14673060
    [No Abstract]   [Full Text] [Related]  

  • 38. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
    Gori S; Anastasi P; Marrocolo F
    Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.
    Kaufmann M; Rody A
    J Cancer Res Clin Oncol; 2005 Aug; 131(8):487-94. PubMed ID: 15915367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Letrozole in breast cancer.
    Shahab N
    N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.